Giuseppe Ciaramella - 21 Jul 2023 Form 4 Insider Report for Beam Therapeutics Inc. (BEAM)

Role
President and CSO
Signature
By: /s/ Christine Bellon, Attorney-in-fact
Issuer symbol
BEAM
Transactions as of
21 Jul 2023
Net transactions value
-$4,350,514
Form type
4
Filing time
25 Jul 2023, 18:36:46 UTC
Previous filing
05 Apr 2023
Next filing
24 Oct 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BEAM Common Stock Options Exercise $501,342 +69,438 +62% $7.22 181,728 21 Jul 2023 Direct F1
transaction BEAM Common Stock Options Exercise $157,728 +21,846 +12% $7.22 203,574 21 Jul 2023 Direct F1
transaction BEAM Common Stock Sale $4,979,687 -155,324 -76% $32.06 48,250 21 Jul 2023 Direct F2, F3
transaction BEAM Common Stock Options Exercise $8,707 +1,206 +2.5% $7.22 49,456 24 Jul 2023 Direct F1
transaction BEAM Common Stock Sale $38,604 -1,206 -2.4% $32.01 48,250 24 Jul 2023 Direct F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BEAM Stock Option (Right to Buy) Options Exercise $0 -69,438 -77% $0.000000 20,208 21 Jul 2023 Common Stock 69,438 $7.22 Direct F1, F5
transaction BEAM Stock Option (Right to Buy) Options Exercise $0 -21,846 -94% $0.000000 1,457 21 Jul 2023 Common Stock 21,846 $7.22 Direct F1, F5
transaction BEAM Stock Option (Right to Buy) Options Exercise $0 -1,206 -6% $0.000000 19,002 24 Jul 2023 Common Stock 1,206 $7.22 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.
F2 These shares of Common Stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $32.00 to $32.11, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $32.00 to $32.095, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 This stock option vests as to 25% on the first anniversary of the vesting commencement date, October 1, 2019, and at a rate of 2.78% each month thereafter until the option is fully vested.